PC
ABUS icon

PointState Capital’s Arbutus Biopharma ABUS Stock Holding History

PointState Capital’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-200,000
Closed -$778K – 67
2021
Q4 		$778K Buy
+200,000
New +$777K 0.01% 114
2014
Q1 		– Sell
-348,000
Closed -$2.77M – 116
2013
Q4 		$2.77M Buy
+348,000
New +$2.9M 0.04% 127

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

PointState Capital's ABUS Position: Q1 2022 in Review

PointState Capital sold out of Arbutus Biopharma (ABUS) in Q1 2022, closing a stake of 200,000 shares — an estimated $778K sold.

PointState Capital first reported a position in ABUS in Q4 2013 and held it in 2 quarters. The position peaked at $2.77M in Q4 2013. 119 funds tracked by Wall St. Rank hold ABUS as of Q1 2022.

  • PointState Capital reported no remaining Arbutus Biopharma position as of Q1 2022 after selling out during the quarter.
  • PointState Capital sold 200,000 Arbutus Biopharma shares in Q1 2022, an estimated $778K.
  • PointState Capital first reported a position in Arbutus Biopharma in Q4 2013 and held it in 2 quarters.
  • PointState Capital's Arbutus Biopharma position peaked at $2.77M in Q4 2013.
  • 119 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2022.

Based on PointState Capital's 13F filing for Q1 2022, filed 13 May 2022.